Silence Therapeutics PLC Director/PDMR Shareholding (9678M)

TIDMSLN

RNS Number : 9678M

Silence Therapeutics PLC

03 August 2017

Director/PDMR Shareholding

3 August 2017

Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces that it was advised on 2 August that on that day Alistair Gray, a Non-Executive Director of the Company bought 3,848 Ordinary Shares at 129.75p.

Following this purchase, Alistair Gray is interested in 3,848 ordinary shares, 0.01% of the issued share capital of the Company.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 
 1.   Details of the person discharging managerial 
       responsibilities (PDMR) / person closely associated 
---  --------------------------------------------------------------- 
 a)   Name                   Alistair Gray 
---  ---------------------  ---------------------------------------- 
 2.   Reason for the notification 
---  --------------------------------------------------------------- 
 a)   Position /             PDMR - Non-Executive Director 
       status 
---  ---------------------  ---------------------------------------- 
 b)   Initial notification   Initial notification 
       / Amendment 
---  ---------------------  ---------------------------------------- 
 3.   Details of the issuer, emission allowance market 
       participant, auction platform, auctioneer or 
       auction monitor 
---  --------------------------------------------------------------- 
 a)   Name                   Silence Therapeutics plc 
---  ---------------------  ---------------------------------------- 
 b)   LEI                    213800SSURRJBX85SQ91 
---  ---------------------  ---------------------------------------- 
 4    Details of the transaction(s): section to be 
       repeated for (i) each type of instrument; (ii) 
       each type of transaction; (iii) each date; and 
       (iv) each place where transactions have been 
       conducted 
---  --------------------------------------------------------------- 
 a)   Description            Ordinary Shares in Silence Therapeutics 
       of the financial       plc 
       instrument, 
       type of instrument 
 
       Identification         ISIN for Silence Therapeutics plc 
       code                   Ordinary Shares: 
                              GB00B9GTXM62 
---  ---------------------  ---------------------------------------- 
 b)   Nature of the          Purchase of Ordinary Shares in 
       transaction            Silence Therapeutics plc 
---  ---------------------  ---------------------------------------- 
 c)   Prices(a) and            Price     Volume 
       volume(s)               --------  ------- 
                                129.75p   3,848 
                               --------  ------- 
---  ---------------------  ---------------------------------------- 
 d)   Aggregated 
       information             3,848 Ordinary Shares 
       - Aggregated            GBP4,993 
       volume 
       - Price 
---  ---------------------  ---------------------------------------- 
 e)   Date of the            2 August 2017 
       transaction 
---  ---------------------  ---------------------------------------- 
 f)   Place of the           London Stock Exchange, AIM 
       transaction 
---  ---------------------  ---------------------------------------- 
 

Enquiries:

 
 Silence Therapeutics plc                  Tel: +44 (0)20 
  Ali Mortazavi, Chief Executive Officer    3457 6900 
  David Ellam, Chief Financial Officer 
 
 Peel Hunt LLP (Nominated Adviser          Tel: +44 (0)20 
  and Broker)                               7418 8900 
  James Steel/Oliver Jackson 
 Media Enquiries:                          Tel: +44 (0) 
  FTI Consulting                            20 3727 1000 
  Simon Conway/Brett Pollard/Stephanie 
  Cuthbert 
 

Notes to Editors

About Silence Therapeutics plc

Silence Therapeutics develops a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHDDGDICSGBGRD

(END) Dow Jones Newswires

August 03, 2017 02:02 ET (06:02 GMT)